SYNKLINO
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
SYNKLINO
Social Links:
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Lyngby, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.synklino.com
Total Employee:
1+
Status:
Active
Contact:
+45 20 12 16 56
Email Addresses:
[email protected]
Total Funding:
31.99 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail
Similar Organizations
Acthera Therapeutics
Acthera Therapeutics is developing an innovative nanotechnology-based platform for the controlled and targeted drug delivery
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Current Advisors List
Current Employees Featured
Investors List
EIR Ventures
EIR Ventures investment in Series A - Synklino
PKA
PKA investment in Series A - Synklino
Maj Invest Equity
Maj Invest Equity investment in Series A - Synklino
Vaekstfonden
Vaekstfonden investment in Series A - Synklino
Vaekstfonden
Vaekstfonden investment in Seed Round - Synklino
EIR Ventures
EIR Ventures investment in Seed Round - Synklino
Official Site Inspections
http://www.synklino.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K
- Host name: linux12.scannet.dk
- IP address: 185.21.43.12
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
